Valbiotis : Un appel au marché en amont d’une commercialisation en 2024
>Une augmentation de capitale de 15 M€ intégrant une décote de 20,1% - Valbiotis a annoncé hier soir post marché le lancement d’une augmentation de capital avec suppression du Droit Préférentiel de Souscription (DPS) d’un montant de 15 M€ (3,4M d’actions nouvelles) correspondant à 22% de la capitalisation de la société. Les modalités de souscription sont connues à savoir une action nouvelle au prix de 4,46 € ce qui correspond à une décote de 20,1% par rapport au cours...Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.